fbpx

Day

October 8, 2020
Aarhus, Denmark, 6 October 2020 – NMD Pharma A/S, a biotech company leading in the development of novel therapeutics for neuromuscular disorders, today announces that the first subject has been dosed in a Phase I/IIa clinical trial of NMD670, NMD Pharma’s lead program in development to treat the symptoms of myasthenia gravis (MG). The trial...

News

Brain stimulation to relieve symptoms of Parkinson’s disease
25. January 2021
Mini-Brains to shed light on nervous disorders
25. January 2021
Mechanisms of schizophrenia
25. January 2021

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge